LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Grifols and Inpeco Partner to Deliver Transfusion Medicine ‘Lab of The Future’

By LabMedica International staff writers
Posted on 21 Mar 2025
Image: Inpeco’s new open automation system FlexLab X will enable Grifols solutions to interconnect with, and expand within, existing and future lab footprints (Photo courtesy of Inpeco)
Image: Inpeco’s new open automation system FlexLab X will enable Grifols solutions to interconnect with, and expand within, existing and future lab footprints (Photo courtesy of Inpeco)

Grifols (Barcelona, Spain), a manufacturer of plasma-derived medicines and innovative diagnostic solutions, has entered into a strategic agreement with Inpeco (Novazzano, Switzerland), a global leader in total laboratory automation technologies, to provide transfusion medicine labs with complete, tailored instrumentation, robotics, and software capabilities to modernize their operations and make them more efficient.

The partnership adds to Grifols’ global leadership in instrumentation, reagents and technical service that screens blood and plasma for possible pathogens as well as performs blood typing for safer transfusions. Grifols, whose technology analyzes tens of millions of donor samples each year, now complements its portfolio with Inpeco’s new open automation system FlexLab™ X, a combination of leading-edge robotics and software that will enable Grifols solutions to interconnect with, and expand within, existing and future lab footprints.

Specifically, Grifols will enhance its industry-leading analytical technologies known for their high throughput and precision with Inpeco’s iconic automation solutions that dispatch sample tubes to Grifols analyzers, among others, and then, after testing, route them to refrigerated storage to further reduce manual intervention while guaranteeing full sample traceability. Digital dashboards provide real-time data on lab performance, while flexible architecture allows to adopt innovations still to come. As part of their collaboration, the two companies are exploring areas in which their combined engineering expertise could deliver more value to transfusion medicine laboratories, which could include technologies that focus on sample pooling, analysis, and transport.

“Grifols is providing the laboratory of the future,” said Antonio Martínez, president of Grifols Diagnostic Business Unit. “We are extremely pleased to join forces with Inpeco, two global lab technology leaders with a complete solution for labs of any size to fully equip their operations knowing they will have the most advanced and scalable technologies today and in the future.”

“At Inpeco, we believe that end-to-end automation is the key to eliminating errors in diagnostic processes,” said Riccardo Triunfo, CEO of Inpeco. “Especially in transfusion medicine, where precision is non-negotiable, our mission is to ensure that labs operate with the highest levels of safety, efficiency and accuracy. Our partnership with Grifols reinforces this vision, enabling laboratories to modernize their operations with confidence.”

Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gold Member
Hematology Analyzer
Medonic M32B

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more